Biomarkers for the detection of aggressive prostate cancers: Application of targeted proteomics to clinically stratified expressed prostatic secretions and urines

用于检测侵袭性前列腺癌的生物标志物：靶向蛋白质组学在临床分层表达的前列腺分泌物和尿液中的应用

• 批准号: 252610
• 负责人: Kislinger Thomas
• 金额: $ 25.27万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-03-01 至 2015-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=252610&lang=en
• 关键词: Biomarker; Prostate Cancer; Prostatic Secretions; Proteomics; Urine

A biomarker is a biological substance that is used to evaluate the presence, progression, or treatment-response of a disease. To be clinically useful, a biomarker should be readily accessible (i.e. body fluids) and provide sufficient sensitivity and speci

生物标志物是用于评估疾病的存在、进展或治疗反应的生物物质。生物标志物要在临床上有用，就应该容易获得（即体液），并提供足够的灵敏度和特异性。